CISON PR Newswire – RLF-100™ therapy associated with a 9-fold increased probability of survival and recovery from respiratory failure in an open-label, prospective study– Top-line data from randomized, placebo-controlled Phase 2b/3 trial expected this quarter GENEVA and RADNOR, Pa., Oct. 13, 2020 /PRNewswire/ — RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF) and NeuroRx, Inc., today announced topline results from 45 […]
CISON PR Newswire Emergency Use Authorization request targets the same population as is currently permitted under FDA Expanded Access Protocol RADNOR, Pa., Sept. 23, 2020 /PRNewswire/ — NeuroRx, Inc. has submitted a request for an Emergency Use Authorization (EUA) with the US FDA for the use of RLF-100™ aviptadil in patients who are receiving intensive care […]
CISON PR Newswire GENEVA, Switzerland and RADNOR, Pa., Sept. 21, 2020 /PRNewswire/ — RELIEF THERAPEUTICS Holding SA (SIX: RLF,OTCQB: RLFTF) (“Relief” or the “Company“) and NeuroRx, Inc. today announced the completion of their partnership agreement for the commercialization of RLF-100™(Aviptadil) worldwide. The two organizations have agreed to share all profits from sales of RLF-100 for […]
CISION PR Newswire – Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA Emergency Use IND authorization at multiple clinical sites – Aviptadil is being developed as the first COVID therapeutic to block replication of the […]
With resurgent COVID-19, enrollment has accelerated in Miami, Houston, and Irvine.
Fast Track Designation of RLF-100 for the treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome associated with COVID-19 underscores the urgent need for new treatment options for these patients.
Clinical trial expanded to patients treated with both noninvasive and mechanical ventilation in Critical COVID-19.
Clinical trial expanded to patients treated with both noninvasive and mechanical ventilation in critical COVID-19.
First participants treated at the University of Miami Miller School of Medicine with intravenous RLF-100.
NeuroRx is leading US development of RLF-100 (Aviptadil) on behalf of Relief Therapeutics’ (RLF).